Evaluation of chromosome 1p/19q deletion by Fluorescence in Situ Hybridization (FISH) as prognostic factors in malignant glioma patients on treatment with alkylating chemotherapy

被引:2
|
作者
Pandith, Arshad A. [1 ,7 ]
Zahoor, Wani [1 ]
Manzoor, Usma [1 ]
Nisar, Syed [2 ]
Guru, Faisal R. [2 ]
Naikoo, Niyaz A. [3 ]
ul Aein, Qurat [1 ]
Baba, Shahid M. [1 ]
Bhat, Abdul R. [4 ]
Ganai, Farooq [5 ]
Shah, Parveen [6 ]
机构
[1] Sher I Kashmir Inst Med Sci SKIMS, Adv Ctr Human Genet, Srinagar, J&k, India
[2] Sher I Kashmir Inst Med Sci SKIMS, Dept Med Oncol, Srinagar, J&K, India
[3] Cluster Univ, Higher Educ Dept, Dept Biotechnol, Srinagar, J&K, India
[4] Sher I Kashmir Inst Med Sci SKIMS, Dept Neurosurg, Srinagar, India
[5] Sher I Kashmir Inst Med Sci SKIMS, Dept CVTS, Srinagar, J&K, India
[6] SKIMS, Dept Pathol, Srinagar, J&K, India
[7] Sher I Kashmir Inst Med Sci SKIMS, Adv Ctr Human Genet, Srinagar, Kashmir, India
关键词
Glioma; Chromosome; 1p/19q; Glioblastoma; Co-deletion; Astrocytoma; DIAGNOSED ANAPLASTIC OLIGODENDROGLIOMAS; PHASE-III TRIAL; ADJUVANT PROCARBAZINE; ADULT GLIOMA; 1P; TUMORS; 19Q; TEMOZOLOMIDE; SURVIVAL; OLIGOASTROCYTOMAS;
D O I
10.1016/j.cancergen.2023.08.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Either deletion or co-deletion of chromosomal arms 1p or 19q is a characteristic and early genetic event in oligodendroglial tumors that is associated with a better prognosis and enhanced response to therapy. Information of 1p/19q status is now regarded as the standard of care when managing oligodendroglial tumors for therapeutic options in anticipation of the increased survival and progression-free survival times associated with it. Keeping this in view, we first time attempted to establish the FISH based detection of 1p/19q deletion in glioma tissue samples to evaluate its role and involvement in the disease.Method: Overall 39 glioma cases of different histologies were evaluated by fluorescence in situ hybridization (FISH) technique using specific FISH probes with Olympus BX43 fluorescent microscope to detect chromosomes 1p and 19q or co-deletions therein.Results: Of the 39 glioma samples, overall 27 (69.2%) were found to have deletion either in 1p, 19q or both. Deletions were observed in 23.0%, 7.6% and 38.4% in 1p, 19q and 1p/19q co-deletions respectively. Overall oligidendrioglioma presented with 53.8% (21 of 39) deletions, astrocytoma group showed 12.8% and GBM accounted for 2.5% deletions. Overall survival and disease free survival was seen significantly better in oligidendrioglioma and astrocytoma with deleted tumors as compared to non-deleted ones (p<0.05).Conclusion: Allelic losses on 1p and 19q, either discretely or shared, were more frequent in classic oligodendrogliomas than in either astrocytoma or Glioblastoma with better survival and response to therapy.
引用
收藏
页码:55 / 61
页数:7
相关论文
共 50 条
  • [31] Development of a Novel FISH Probe for Detection of 1p/19q Codeletion in Routine Glioma Diagnosis
    Satomi, K.
    Yamasaki, K.
    Yoshida, A.
    Wakai, S.
    Matsushita, Y.
    Narita, Y.
    Komori, T.
    Nishikawa, R.
    Ueki, K.
    Ichimura, K.
    JOURNAL OF PATHOLOGY, 2018, 246 : S17 - S17
  • [32] GPGPS: a robust prognostic gene pair signature of glioma ensembling IDH mutation and 1p/19q co-deletion
    Cheng, Lixin
    Wu, Haonan
    Zheng, Xubin
    Zhang, Ning
    Zhao, Pengfei
    Wang, Ran
    Wu, Qiong
    Liu, Tao
    Yang, Xiaojun
    Geng, Qingshan
    BIOINFORMATICS, 2023, 39 (01)
  • [33] Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma
    Polivka, Jiri, Jr.
    Polivka, Jiri
    Repik, Tomas
    Rohan, Vladimir
    Hes, Ondrej
    Topolcan, Ondrej
    ANTICANCER RESEARCH, 2016, 36 (01) : 471 - 476
  • [34] THE CORRELATION BETWEEN RESULTS OF COMPLEX TREATMENT AND 1P/19Q DELETION FOR PATIENTS WITH ANAPLASTIC OLIGODENDROGLIAL TUMORS
    Apskalne, D.
    Ozola, A.
    Bicans, K.
    Ozols, R.
    Auslands, K.
    NEURO-ONCOLOGY, 2014, 16
  • [35] Chromosome 1p and 19q deletions in malignant glioneuronal tumors with oligodendroglioma-like component
    Hiroaki Takeuchi
    Toshihiko Kubota
    Ryuhei Kitai
    Ken Matsuda
    Norichika Hashimoto
    Kazufumi Sato
    Journal of Neuro-Oncology, 2009, 91
  • [36] Chromosome 1p and 19q deletions in malignant glioneuronal tumors with oligodendroglioma-like component
    Takeuchi, Hiroaki
    Kubota, Toshihiko
    Kitai, Ryuhei
    Matsuda, Ken
    Hashimoto, Norichika
    Sato, Kazufumi
    JOURNAL OF NEURO-ONCOLOGY, 2009, 91 (01) : 33 - 38
  • [37] AN INFLAMMATION RESPONSE GENE SIGNATURE IS ASSOCIATED WITH PROGNOSIS OF GLIOMA PATIENTS WITH 1p/19q CO-DELETION TUMORS
    Hu, Xin
    Martinez-Ledesma, Emmanuel
    Zheng, Siyuan
    Kim, Hoon
    Barthel, Floris
    Jiang, Tao
    Hess, Kenneth R.
    Verhaak, Roel
    NEURO-ONCOLOGY, 2016, 18 : 213 - 213
  • [38] Chromosome 1p and 19q evaluation in low-grade oligodendrogliomas: A descriptive study
    Molinari, Chiara
    Iorio, Paulo
    Medri, Laura
    Ballardini, Michela
    Guiducci, Graziano
    Cremonini, Anna Maria
    Cerasoli, Serenella
    Riccioni, Luca
    Faedi, Marina
    Mariani, Giulia Adalgisa
    Zoli, Wainer
    Silvestrini, Rosella
    Calistri, Daniele
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2010, 25 (01) : 145 - 151
  • [39] Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors
    Shukla, Bhaskar
    Agarwal, Shipra
    Suri, Vaishali
    Pathak, Pankaj
    Sharma, Mehar Chand
    Gupta, Deepak
    Sharma, Bhavani Shankar
    Suri, Ashish
    Halder, Ashutosh
    Sarkar, Chitra
    NEUROLOGY INDIA, 2009, 57 (05) : 559 - 566
  • [40] Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas
    Xiong Ji
    Liu Ying
    Wang Yin
    Ke Rong-hu
    Mao Ying
    Ye Zhu-rong
    CHINESE MEDICAL JOURNAL, 2010, 123 (24) : 3566 - 3573